Telomir Pharmaceuticals, Inc. Common Stock Cash Flow-to-Debt Ratio
Telomir Pharmaceuticals, Inc. Common Stock cash flow-to-debt ratio. Telomir Pharmaceuticals, Inc. Common Stock (TELO) has a Cash Flow-to-Debt Ratio of -2.14x as of March 2026, meaning its operating cash flow of $-1.77 Million could theoretically repay -2% of its total liabilities ($827.31K) in one year. See financial agility of Telomir Pharmaceuticals, Inc. Common Sto to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Telomir Pharmaceuticals, Inc. Common Stock (2021–2025)
Cash flow-to-debt ratio of Telomir Pharmaceuticals, Inc. Common Stock from 2021 to 2025. Historical debt coverage capacity for Telomir Pharmaceuticals, Inc. Common Stock across 5 annual periods. Also explore Telomir Pharmaceuticals, Inc. Common Sto (TELO) net asset momentum to track the company's year-over-year net asset growth rate.
Telomir Pharmaceuticals, Inc. Common Stock Cash Flow-to-Debt Ratio by Year (2021–2025)
Telomir Pharmaceuticals, Inc. Common Stock cash flow-to-debt ratio by year from 2021 to 2025. Year-by-year debt coverage analysis for Telomir Pharmaceuticals, Inc. Common Stock. For the full cash flow conversion analysis, see TELO operating cash flow.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.58x | $-3.69 Million | $1.43 Million | ▲ +65.3% |
| 2024 | -7.45x | $-5.07 Million | $680.97K | ▼ -157.6% |
| 2023 | -2.89x | $-3.86 Million | $1.34 Million | ▼ -508.0% |
| 2022 | -0.48x | $-468.66K | $986.01K | ▲ +45.0% |
| 2021 | -0.86x | $-119.40K | $138.13K | — |